Novartis’ Newly Licensed Antidepressant Hits Snag In EU Under Separate Sponsor
This article was originally published in The Pink Sheet Daily
Executive Summary
EMEA’s review committee recommends against authorization of agomelatine, but sides with Gardasil and Champix/Chantix.
You may also be interested in...
EMEA Issues Negative Opinion For Novartis’ Anti-Infective Mycograb
Firm also receives positive opinions from EU authorities on hypertension combo Exforge and macular degeneration treatment Lucentis.
EMEA Issues Negative Opinion For Novartis’ Anti-Infective Mycograb
Firm also receives positive opinions from EU authorities on hypertension combo Exforge and macular degeneration treatment Lucentis.
CDC Adds Merck’s Gardasil To Vaccines For Children Contract
The HPV vaccine received European approval in September.